HOME >> MEDICINE >> NEWS
NOVANTRONE application for multiple sclerosis granted priority review by FDA

FDA review of NOVANTRONE data to be completed within six months

SEATTLE-Immunex Corporation (NASDAQ:IMNX) announced today that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the new drug application (NDA) for NOVANTRONER (mitoxantrone for injection concentrate), indicating that the FDA will act on the application within six months of its date of submission. Immunex filed for expanded labeling for NOVANTRONE for the treatment of patients with secondary progressive multiple sclerosis (MS) on June 7, 1999.

"This is an important milestone in the development of NOVANTRONE as a potential treatment for people with secondary progressive MS," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "We will continue to work closely with the FDA over the next six months as they evaluate these data."

The results of the pivotal NOVANTRONE Phase III study showed that NOVANTRONE had a statistically significant impact on reduction of relapse rate and delay in disability progression in patients with secondary progressive MS. Additional follow-up data presented at a recent international conference showed that one year after treatment was stopped, patients treated with NOVANTRONE continued to experience a reduction in their number of attacks, and a delay in their disability progression.

In the study, treatment with NOVANTRONE resulted in generally manageable side effects that were primarily mild to moderate. During the two-year trial, the most frequent side effects reported by patients treated in the 12 mg/m2 arm were nausea, alopecia (hair loss), upper respiratory tract infection, urinary tract infection, menstrual disorder, and transient neutropenia (a reduced number of white blood cells).

Multiple sclerosis is a chronic, debilitating disease of the central nervous system that, in its various stages, afflicts as many as 350,000 people in the Unit
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
19-Jul-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Considerable reductions in radiation exposure possible with 16-MDCT scanner on body applications
3. AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
4. Roche files marketing application for Avastin with European health authorities
5. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Research suggests possible blood test for multiple sclerosis
8. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma
9. Good fats decrease multiple heart disease risk factors
10. Swallowing multiple magnets poses danger to children
11. Sleep disorders often indicate multiple health conditions

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri ... whitening treatments. A professional teeth whitening is one of the fastest, easiest ways to ... as they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... America ... others. California Casualty’s Nominate A Hero program offers a special way to ... a well-deserving hero receives a $250 gift card and their place on the “Wall ...
(Date:7/7/2015)... ... July 07, 2015 , ... Office ... the company’s new Chief Financial Officer, effective July 6th, 2015. Ellen joins Office ... ranging from a multi-billion dollar, global chemical company to early and growth-stage technology ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... motivated leaders with strong managerial expertise to oversee large healthcare operations and ... staff, providers, business partners, insurance companies, and regulators. American Sentinel University, an ...
(Date:7/7/2015)... IL (PRWEB) , ... July ... ... Inc., a leading provider of unified communication management solutions, has announced the ... Infortel® Select. , This service pack includes a number of enhancements to ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:Office Practicum Announces new CFO 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2
(Date:7/7/2015)... , July 7, 2015  Essentialis, a venture-backed company ... for the treatment of orphan neurobehavioral and metabolic diseases, today ... CSO, will present a corporate update at the Cantor Fitzgerald ... Date: Wednesday, July 8, 2015 Time: 8:00 ... About Essentialis, Inc. Essentialis ...
(Date:7/7/2015)... , July 7, 2015 Oramed ... a clinical-stage pharmaceutical company focused on the development of ... signed a non-binding Letter of Intent (LoI) for an ... with Sinopharm Capital Management Co. Ltd. and Hefei ... Ltd. (Sinopharm/ Hefei ) potentially valued at ...
(Date:7/6/2015)... July 6, 2015  Student-athletes at community colleges ... from a recently established partnership between ImPACT Applications, ... . The partnership enables member institutions of ... ImPACT ® concussion baseline and post-injury testing ... of community colleges in California ...
Breaking Medicine Technology:Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 2Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 3Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 4Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 5California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 2California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 3
Cached News: